Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team
Round Type
Series B
Palo AltoBiotechnologyHealth CareInvestors
Description
Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the closing of an additional $7.5 million to its Series B financing from new investor Verition Fund Management, bringing the total raised in the Series B round to $57.5 million. The company previously announced the closing of the initial $50 million in April 2023. In addition, the company also announced the appointment of J. Mark Jackson, MD, as Vice President, Clinical Development.
Quick answer
Evommune raised an undisclosed amount in a Series B round, dated June 28, 2023. Investors: Verition Fund Management. Evommune is based in Palo Alto, California, United States.
- How much did Evommune raise?
- Evommune raised an undisclosed amount in a Series B round on June 28, 2023.
- Who invested in Evommune?
- Verition Fund Management is named as investors in this round.
- What does Evommune do?
- Evommune, Inc. is a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases.
- Where is Evommune based and how big is it?
- Evommune is based in Palo Alto, California, United States. Fundz records about 45 employees.
- Who are the decision-makers at Evommune?
- Fundz holds 1 contact at Evommune. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Evommune that raised within 45 days of this round, from Fundz verified event records.
- Abcuro raised $120M on August 11, 2023.
- MindMed raised $7M on August 11, 2023.
- Zetagen Therapeutics raised an undisclosed amount (Series B) on August 11, 2023.
- HAGAR raised an undisclosed amount (Funding Round) on August 10, 2023.
- ADARx Pharmaceuticals, Inc. raised $200M (Series C) on August 9, 2023.
- Fore Biotherapeutics raised $62M on August 9, 2023.
Who to call at Evommune, and when
A new round usually means Evommune is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Evommune raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Evommune, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Evommune. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Evommune raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansEvommune raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.